Literature DB >> 19219405

Comparison of pain and ecchymosis with low-molecular-weight heparin vs. unfractionated heparin in patients requiring bridging anticoagulation after warfarin interruption: a randomized trial.

Erin Jamula1, Karen Woods, Madeleine Verhovsek, James D Douketis, Ellen McDonald.   

Abstract

BACKGROUND: Subcutaneous (SC) low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH) are safe and efficacious for bridging anticoagulation after warfarin interruption. Although LMWH and UFH are self-administered by >90% of patients, factors that may be important to patients such as differences in pain and ecchymosis have not been explored.
METHODS: We randomized 24 patients to receive SC LMWH or SC UFH twice-daily during the perioperative period. Injection associated pain was recorded using a visual analogue scale and area of ecchymosis was measured by digital photography of the injection site on the day of the procedure.
RESULTS: The area of ecchymosis was 2-fold higher with UFH than LMWH (19.4 cm(2) vs. 8.98 cm(2); P = 0.33) and pain was similar with both treatments (115 mm vs. 171 mm; P = 0.25), though neither finding attained statistical significance.
CONCLUSIONS: This exploratory study was underpowered to detect differences between the groups. Further studies are needed to reliably compare pain and ecchymosis in LMWH vs. UFH.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19219405     DOI: 10.1007/s11239-009-0312-8

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  6 in total

1.  Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism.

Authors:  Clive Kearon; Jeffrey S Ginsberg; Jim A Julian; James Douketis; Susan Solymoss; Paul Ockelford; Sharon Jackson; Alexander G Turpie; Betsy MacKinnon; Jack Hirsh; Michael Gent
Journal:  JAMA       Date:  2006-08-23       Impact factor: 56.272

Review 2.  Perioperative anticoagulation management in patients who are receiving oral anticoagulant therapy: a practical guide for clinicians.

Authors:  James D Douketis
Journal:  Thromb Res       Date:  2002-10-01       Impact factor: 3.944

3.  Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry.

Authors:  A C Spyropoulos; A G G Turpie; A S Dunn; J Spandorfer; J Douketis; A Jacobson; F J Frost
Journal:  J Thromb Haemost       Date:  2006-06       Impact factor: 5.824

4.  The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  James D Douketis; Peter B Berger; Andrew S Dunn; Amir K Jaffer; Alex C Spyropoulos; Richard C Becker; Jack Ansell
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

5.  Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen.

Authors:  James D Douketis; Judith A Johnson; Alexander G Turpie
Journal:  Arch Intern Med       Date:  2004-06-28

6.  Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism.

Authors:  Paolo Prandoni; Marino Carnovali; Antonio Marchiori
Journal:  Arch Intern Med       Date:  2004-05-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.